Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
88.68-1.76 (-1.94%)
As of 3:13PM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 90.44 |
| Open | 90.17 |
| Bid | 88.88 x 900 |
| Ask | 88.92 x 900 |
| Day's Range | 88.66 - 90.92 |
| 52 Week Range | 62.48 - 110.37 |
| Volume | 390,754 |
| Avg. Volume | 1,118,623 |
| Market Cap | 19.395B |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.89 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 106.40 |
- Investor's Business Daily
Novartis Earnings Top, Sales Miss; NVS Stock Falls
Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant. Shares fell.
- Investor's Business Daily
LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials
Eli Lilly early Tuesday posted third-quarter earnings and sales that missed Wall Street expectations and said that one of its Covid-19 treatments failed in clinical trials; LLY stock fell.
- CNW Group
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
MONTREAL, Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has accepted its New Drug Submission (NDS) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
© 2020 Verizon Media. All rights reserved.
